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MAY THE BEST FRIEND BE AN ENEMY 
IF NOT RECOGNIZED EARLY
Possible role of omega-3 against cardiovascular abnormalities 
due antipsychotics in the treatment of autism
Roberta M. Cysneiros1, Vera C. Terra2, Hélio R. Machado2, Ricardo M. Arida3,  
José Salomão Schwartzman1, Esper A. Cavalheiro4, Fulvio A. Scorza4
Abstract – Autism spectrum disorders (ASD) are neurodevelopment disorders that cause severe and pervasive 
impairment in socialization, communication, and behavior. Although the availability of antipsychotic treatment 
in ASD has expanded, we will be very careful with side effects of these pharmacological agents. Following 
this reasoning, emerging data indicate that some antipsychotics may be associated with cardiovascular 
adverse events (e.g., QT interval prolongation), suggesting that this could be correlated to sudden death. 
Quite interesting, substantial evidence from epidemiological and case-control studies indicates that omega-3 
reduces the risk of cardiovascular mortality, particularly sudden cardiac death. In accordance to the above 
mentioned findings, as omega-3 fatty acids per se have a direct cardiovascular protective role, our paper 
hypothesized that omega-3 fatty acids supplementation in ASD patients treated with atypical antipsychotic 
drugs may reduce cardiac arrhythmias and hence sudden cardiac death. 
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Pode um melhor amigo ser um inimigo se não reconhecido a tempo: possível papel do ômega-3 nos efeitos 
cardiovasculares secundários ao tratamento antipsicótico de pacientes com autismo
Resumo – As desordens do espectro autista (DEA) são um grupo de doenças do desenvolvimento que causam 
um grave comprometimento na socialização, comunicação e comportamento. Embora o tratamento na DEA 
com drogas antipsicóticas tenha se expandido, é necessária a observação cuidadosa de efeitos colaterais 
destes fármacos. Nesta linha, dados recentes têm associado o uso de antipsicóticos com efeitos adversos 
cardiovasculares (como prolongamento do intervalo QT), sugerindo que possa haver uma correlação com 
morte súbita. Evidências originadas em dados epidemiológicos e estudos de caso-controle indicam que o 
Omega-3 reduz o risco de mortalidade por causa cardiovascular, particularmente a morte súbita de origem 
cardíaca. Concordante com estes achados, como o Omega-3 per se tem um papel protetor cardiovascular 
direto, nosso artigo levanta a hipótese que a suplementação de ácidos graxos Omega-3 em pacientes com DEA 
tratados com drogas antipsicóticas podem reduzir o risco de arritmias cardíacas e assim a morte súbita cardíaca.
PALAVRAS- CHAVE: desordens do espectro autista, coração, morte súbita, ômega 3.
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AuTISM: GENERAL ASPECTS
Autism spectrum disorders (ASD) are neurodevelop-
mental disorders that cause severe and pervasive impair-
ment in socialization, communication, and behavior1,2. 
These include poor eye contact, deficits in other non-
verbal social behaviors, social withdrawal, impaired so-
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cial reciprocity, echolalia, motor stereotypes, intense and 
circumscribed interests, and a preoccupation with parts of 
objects instead of the whole1,2. These disorders are usual-
ly first diagnosed in early childhood and range from au-
tistic disorder, through pervasive development disorder 
not otherwise specified, including Asperger syndrome2. 
The ASD are more common in the pediatric population 
than are some better known disorders such as diabetes, 
spinal bifida, or Down syndrome3. Prevalence studies have 
been done in different populations, including USA, Unit-
ed Kingdom, Europe, and Asia. A recent study of a U.S. 
metropolitan area estimated that 3.4 of every 1,000 chil-
dren 3-10 years old had autism4. The specific cause of au-
tism is unknown, however, evidence from twin and fam-
ily studies indicates that autism is highly heritable1, neu-
rochemical investigations have identified abnormalities in 
monoamines, glutamate, y--amino hydroxybutyrate, and 
neuropeptides1,5, functional neuroimaging studies are be-
ginning to demonstrate differences between the brains 
of persons with autism and those of controls1,6 and brain 
regions potentially involved in autism and related disor-
ders are diverse and include the amygdale, cerebellum, 
fusiform gyrus, and prefrontal cortex1,7. 
Although the availability of antipsychotic treatment 
in ASD has expanded, we should consider it very careful 
because of these pharmacological agents’ side effects. In 
these way, emerging data indicate that some antipsychot-
ics may be associated with cardiovascular adverse events 
(e.g., QT interval prolongation), suggesting that this could 
leads to torsade the points or sudden death8. Quite in-
teresting, substantial evidence from epidemiological and 
case-control studies indicates that omega-3 reduces the 
risk of cardiovascular mortality, particularly sudden car-
diac death9. In accordance to the above mentioned find-
ings, as omega-3 fatty acids per se have a direct cardio-
vascular protective role9,10, we hypothesized that omega-3 
fatty acids supplementation in ASD patients treated with 
atypical antipsychotic drugs may reduce cardiac arrhyth-
mias and hence sudden death.
OMEGA-3 AND CARDIOVASCuLAR SYSTEM: 
ANTIARRHYTHMIC PROPERTIES AND 
PREVENTION OF SuDDEN CARDIAC DEATH
The beneficial effects of omega-3 fatty acids in the 
cardiovascular system have been described since the sev-
enties. Dyerberg and Bang11 demonstrated that the low 
prevalence of cardiac diseases in Eskimos might proba-
bly be due to high dietary ingestion of omega-3 fatty ac-
ids. In the same decade, a number of experimental studies 
showed an antiarrhythmic role of the omega-3 fatty acid12. 
In this line, McLennan and Charnock, two Australians re-
searchers, conducted several experiments to confirm the 
possible antiarrhythmic role of omega-3. Initially, it was 
demonstrated that a dietary composed from fish oil (tuna) 
could prevent the ventricular fibrillation in rats induced 
by coronary artery occlusion following reperfusion13,14. 
Subsequent studies confirmed their previous data15,16. Bil-
man and colleagues using a sudden cardiac death model 
in dogs observed a reduction of arrhythmias and sudden 
cardiac death following ischemia induction after omega-3 
administration17,18. Moreover, several works demonstrated 
positive effects of omega-3 in arrhythmia reduction19-23. 
The antiarrhythmic mechanism induced by omega-3 was 
modulated by Na+ and Ca2+ currents in cardiac cells24. In 
the same way, positive effects of omega-3 have been also 
observed in clinical studies. Accordingly, several studies 
in the nineties demonstrated that fish consumption, 1 or 
2 times per week were associated to a 50% reduction of 
sudden cardiac death25,26. Furthermore, a clinic study for 
infarct prevention conducted by an Italian group (GISSI-
Prevenzione), using an dose of 850 mg/day de omega-3 in 
11324 subjects presenting a first myocardial infarction epi-
sode, observed a significant reduction of death caused by 
cardiovascular complications (30%) as well as in sudden 
death (45%) when compared to control subjects, suggest-
ing an antiarrhythmic role of omega-327,28. In conclusion, 
human and animals studies have demonstrated a possi-
ble action of omega-3 in the prevention of cardiovascu-
lar abnormalities and reduction of occurrence of sudden 
cardiac death.
ATYPICAL ANTIPSYCHOTICS DRuGS, AuTISM 
AND CARDIOVASCuLAR ABNORMALITIES
Antipsychotic therapy has become indispensable in 
the treatment of a variety of symptoms in ASD1 and sev-
eral evidences shows that atypical antipsychotics are con-
sidered more effective than conventional antipsychotics 
in treating certain symptoms associated with ASD, such 
as aggression, irritability, and self-injurious behavior29. In 
these lines, the atypical antipsychotics risperidone, olan-
zapine, quetiapine and ziprazidone are the most common-
ly prescribed for ASD1,29. Concerning risperidone, sever-
al studies shows that this psychotropic atypical antipsy-
chotic agent offers a valuable emerging option for the 
treatment of irritability associated with autistic disorder 
in children and adolescents30. Olanzapine and quetiap-
ine have shown minimal clinical benefit in ADS based on 
clinical trials published at the moment1,29. Concerning zip-
razidone, the use of this atypical antipsychotic in ASD 
remains limited, however, a single case series of 12 pa-
tients aged 8−20 years found improvements in the areas 
of aggression, agitation, and irritability, suggesting a future 
promise as a treatment for adolescents with ASD31.
In accordance to this reasoning, a pertinent question 
could be evaluated: should the physician pay more atten-
tion with possible cardiac abnormalities during atypical 
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antipsychotic treatment in ASD? Although the incidence 
of serious adverse cardiac events in response to atypical 
antipsychotic medications is relatively low, some consid-
erations should be made. For example, Ravin and Levenson 
described a patient who developed fatal pulseless electri-
cal activity following initiation of risperidone therapy, sug-
gesting that prolongation of the QTc interval with severe 
adverse effects remains a possibility with the use of this 
atypical antipsychotic32. Recently, Janion and colleagues33 
reported a case of a 53 year old female with olanzapine-
induced QT interval prolongation and fatal ventricular fi-
brillation, suggesting that all antipsychotic drugs have the 
potential for serious adverse events. In 2004, Kurt and 
Maguire called our attention about the risk of QTc inter-
val prolongation associated with quetiapine administra-
tion34. They related a 14-year-old boy who ingested 1900 
mg of quetiapine. One and one half hours after inges-
tion, the QTc interval lengthened from 453 msec to 618 
msec on the printout (manual calculation was 444 msec 
to 500 msec, respectively), suggesting a relationship be-
tween higher doses of quetiapine, higher serum levels and 
the propensity for QTc interval prolongation. Concerning 
ziprasidone, Posey and co-workers1 related in an elegant 
review article, the potential for QTc interval prolonga-
tion with this drug on electrocardiography led to a warn-
ing in the full prescribing information. The authors sug-
gested that ziprasidone should not be given to individu-
als with cardiac arrhythmias or long QT syndrome or who 
take other medications that can prolong the QTc interval.
CONCLuSIONS AND FuTuRE REMARKS
As related before, emerging data indicate that some 
atypical antipsychotics prescribed for ASD may be asso-
ciated with cardiovascular adverse events (e.g., QT inter-
val prolongation), suggesting that this could leads to tor-
sade the points or sudden death8. Although the availabil-
ity of pharmacological treatment of ASD has expanded, 
the atypical antipsychotic drugs are still limited in clin-
ic efficacy1. In these lines, several factors such as genetic, 
environmental and social can contribute to the inefficacy 
of therapeutic outcome patients with ASD. Among these 
factors, nutritional aspects, i.e., omega-3 fatty acids defi-
ciency should also have an interesting role in this scenario. 
In accordance to these findings, as omega-3 fatty acids per 
se have a direct cardiovascular protective role (e.g., reduce 
serum triglycerides levels, cardiovascular disease preven-
tion, antiarrhythmic effects, treatment after a myocardi-
al infarction, and secondary prevention of cardiovascular 
disease)9,10, we believe that omega-3 fatty acids fatty acid 
supplementation in patients with ASD and treated with 
atypical antipsychotics may reduce cardiac arrhythmias 
and hence sudden death. In parallel, it is interesting to 
note that this hypothesis was evaluated by our and others 
research groups in schizophrenia35,36, one of the most se-
vere forms of mental illness associated with an increased 
risk of cardiac sudden unexpected death and which pa-
tients make use of antipsychotics drugs. For instance, in a 
dose-ranging exploratory study of eicosapentaenoic acid 
(EPA) in 115 patients treatment-resistant schizophrenia (31 
on clozapine, 48 on new atypical drugs and 36 on typical 
antipsychotics), subjects received 1, 2 or 4 g/day of ad-
junctive EPA or placebo for 12 weeks37. In patients on clo-
zapine, a clinically important and statistically significant 
effect of EPA was noted (greatest effect at 2 g/day)37. Im-
provement correlated positively with a rise in erythro-
cyte arachidonic acid (AA) concentration. Additionally, 
clozapine-treated patients who received EPA 2 and 4 g/
day showed significant reduction in triglyceride levels that 
were elevated previously during clozapine use37.
In the general population, clinical studies of ome-
ga-3 fatty acids have shown a reduction in sudden cardi-
ac death, suggesting that omega-3 may have antiarrhyth-
mic effects38. Moreover, a relationship between red blood 
cell (RBC) membranes omega-3 fatty acids levels and risk 
for sudden cardiac death have been reported as well39. 
Similarly, deficits in red blood cell omega-3 fatty acids 
have been reported in medicated psychotic subjects41,49. 
Quite interesting, compelling evidence was found that a 
low dietary of omega-3 fatty acids in conjunction with 
sedentary behavior and mental stress combined with var-
ious personality traits can enhance sympathetic activity 
and increase the secretion of catecholamine, cortisol and 
serotonin, all of which appear to be underlying mecha-
nisms involved in metabolic syndrome42, a potentially cat-
astrophic multiplex risk factor for cardiovascular disease 
and hence sudden cardiac death in patients prescribed 
with antipsychotic drugs. 
Concerning specifically the pediatric population, Van-
cassel et al. in an elegant study demonstrated a reduc-
tion in polyunsaturated fatty acids and aracdonic acids in 
Table. Primary dietary source of omega-3 fatty acids. Adapted 
by permission of Dr. Marianna Mazza45.
Fish oils Plant oils
Salmon Flaxseeds
Mackerel Flaxseed oil
Halibut Canola (rapeseed) oil
Sardines Soybeans
Herrings Soybean oil
Anchovies Pumpkin seeds
Tuna Pumpkin seed oil
Oyster Purslane
Lobster Walnuts
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ASD and in mentally retarded patients, when compared to 
normal patients. Similar variations have been described in 
other psychiatric diseases, such as schizophrenia, atten-
tion deficit and hyperactivity disease, major depression 
and bipolar disorders, compared to control subjects43. The 
authors proposes this could represent an additional ap-
proach to the treatment of autism, through polyunsat-
urated fatty acids dietary supplementation43. Other au-
thors, in a pilot study suggested the effectiveness of fish 
oil supplementation to reduce hyperactivity in 12 chil-
dren with ASD. Considering this data together, it seems 
that polyunsaturated fatty acids serum levels may play 
an important role in the mechanisms of development of 
behavioral diseases44.
Where do we go from here? We are sure that more 
needs to be done and on the basis of laboratory data and 
clinical findings, there are reasons to suggest that ome-
ga-3 may offer a host of benefits to people with ASD. As 
we know, omega-3 fatty acids are long-chain, polyunsatu-
rated fatty acids found in plant and marine sources45 (Ta-
ble). Actually, it has long been believed that a daily intake 
of 3000 to 4000 mg of fish oil supplements or 2 to 3 serv-
ings of fatty fish per week are safe and effective to adults 
in general, included those with psychiatric disorders45. In 
this way, new considerations and experimental, epidemi-
ological and clinical studies should be evaluated to estab-
lish with precision the relationship between omega 3 fat-
ty acids, atypical antipsychotic and ASD.
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